ARCA biopharma, Inc. (ABIO)
After hours:
| Previous Close | 2.0800 |
| Open | 2.0500 |
| Bid | 2.0000 x 3200 |
| Ask | 2.1900 x 1000 |
| Day's Range | 2.0100 - 2.1400 |
| 52 Week Range | 1.7600 - 2.7000 |
| Volume | |
| Avg. Volume | 35,245 |
| Market Cap | 30.405M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings Date | May 01, 2023 - May 05, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Th
- Simply Wall St.
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
James Flynn Joins ARCA biopharma Board of Directors
WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium
